Gilead Offers Up $4.3bn For CymaBay And Phase III PBC Candidate

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Adding to its liver disease portfolio, Gilead agreed to pay a 27% premium for CymaBay and seladelpar, which has a 14 August FDA action date to compete in second-line primary biliary cholangitis.

Gilead
Gilead adds in liver with CymaBay acquisition • Source: Shutterstock: Tada Images

Gilead Sciences, Inc. is bolstering its strength in liver disease by going outside of viral hepatology with a $4.3bn agreement to acquire CymaBay Therapeutics, Inc. and its Phase III candidate for second-line primary biliary cholangitis (PBC) seladelpar. The deal was announced before the markets opened on 12 February, with Gilead stating that both companies’ boards had approved the $32.50-per-share offer and predicting that the transaction would close before the end of Q1.

Key Takeaways

  • Gilead and CymaBay have agreed on a $4.3bn takeout, which would be a 27% per-share premium for the latter company.

Gilead is already a titan of the liver disease space with its strong-selling hepatitis B and hepatitis D franchise and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.